Oxford BioDynamics Plc (AIM:OBD)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.2150
-0.0100 (-4.44%)
Dec 31, 2025, 12:34 PM GMT+1
-85.17%
Market Cap9.23M
Revenue (ttm)1.10M
Net Income (ttm)-11.15M
Shares Out4.29B
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,061,741
Average Volume19,652,153
Open0.2121
Previous Close0.2250
Day's Range0.2025 - 0.2200
52-Week Range0.2025 - 1.6000
Beta-0.64
RSI26.61
Earnings DateDec 16, 2025

About Oxford BioDynamics

Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy. EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarker. Its p... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 41
Stock Exchange London Stock Exchange AIM
Ticker Symbol OBD
Full Company Profile

Financial Performance

In 2025, Oxford BioDynamics's revenue was 1.10 million, an increase of 72.17% compared to the previous year's 636,000. Losses were -11.15 million, -3.58% less than in 2024.

Financial Statements

News

AIM Market Roundup: TPXImpact, Petards, RC Fornax

TPXImpact, Petards, RC Fornax are today's top risers, while Pantheon Resources, Oxford Biodynamics take the biggest fall on London's AIM

4 weeks ago - The Armchair Trader

AIM Market Roundup: Proteome Sciences, Greenroc Strategic Minerals, IQE

Proteome, Greenroc, IQE are today's top risers, while Polarean Imaging, Oxford Biodynamics take the biggest fall on AIM

2 months ago - The Armchair Trader

Oxford BioDynamics has important role in future cancer screening says report

Oxford BioDynamics has welcomed a new report that calls for the introduction of targeted prostate cancer screening in the UK.

2 months ago - The Armchair Trader

AIM Market Roundup: WH Ireland, Bradda Head, Oxford Biodynamics

WH Ireland, Bradda Head, Oxford Biodynamics are today's top risers, while Mercantile Ports, Angle take the biggest fall on London's AIM market

3 months ago - The Armchair Trader

AIM Market Roundup: Oxford Biodynamics, GCM Resources, ECO Animal Health

Oxford Biodynamics, GCM, ECO Animal Health are today's top risers, while Cirata, Caledonian Holdings take the biggest fall on London's AIM

6 months ago - The Armchair Trader

AIM Market Roundup: Marechale, Oxford Biodynamics, SDX Energy

Marechale, Oxford Biodynamics, SDX Energy, Proton Motors, Vast Resources are today's biggest risers and fallers on London's AIM market

1 year ago - The Armchair Trader

Small Cap Stocks: i-nexus Global, Genip, Oxford Biodynamics

i-nexus Global, Genip, Quadrise, Oxford Biodynamics, XLMEDIA are today's biggest Small Cap stock movers

1 year ago - The Armchair Trader

Three Quick Facts: Oxford Biodynamics, Entain, Computacenter

Swift CEO departure at Oxford Biodynamics, regulatory action vs Entain (Australia) could be costly, CCC CFO OOO: leaves company at year-end

1 year ago - The Armchair Trader

Small Cap Stocks: Brand Architekts, tinybuild, Quadrise

Brand Architekts, tinybuild, Quadrise, Gfinity, Oxford Biodynamics are today's biggest Small Cap stock movers

1 year ago - The Armchair Trader

Small Cap Stocks: Rockfire Resources, Fusion Antibodies, Oracle Power

Rockfire Resources, Fusion Antibodies, Surface Transforms, Oracle Power, Oxford Biodynamics are today's biggest Small Cap stock movers

1 year ago - The Armchair Trader

Small Cap Stocks: Empyrean, Seascape, Mirriad

Empyrean Energy, Seascape Energy, Oxford Biodynamics, Mirriad Advertising, Empresaria are today's biggest Small Cap stock movers

1 year ago - The Armchair Trader

Oxford Biodynamics shares plummet as company faces cliff edge

Oxford Biodynamics reports increased orders for prostrate cancer test, but high cash-burn leads to strategic review and cost cutting measures

1 year ago - The Armchair Trader